No surprise: FDA hands Pain Therapeutics another slapdown on Remoxy, forcing a quick restructuring
Just as expected, the FDA has once again hit Pain Therapeutics $PTIE with a rejection of its application to sell Remoxy. And the biotech’s CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
